Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at observing the clinical effects of sacubitril/valsartan combined with dapagliflozin ...

Sacubitril/valsartan significantly reduced cardiomyopathy risk by 77% in patients on anthracycline chemotherapy compared to placebo. The SARAH trial highlights the need to identify high-risk patients ...

Please provide your email address to receive an email when new articles are posted on . Declines in estimated glomerular filtration rate after transition to sacubitril/valsartan for HF are mild and ...

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although ...